Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Tacrolimus (DB00864)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00053989Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic AnemiaTreatment
NCT00002792Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative DisordersTreatment
NCT00096096Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationSupportive Care
NCT00109993Campath-1H + FK506 and Methylprednisolone for GVHDSupportive Care
NCT00134004Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerTreatment
NCT00346359Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid CancerTreatment
NCT00589563Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerSupportive Care